Epizyme, Inc. (EPZM)
(Delayed Data from NSDQ)
$12.10 USD
+0.19 (1.60%)
Updated May 3, 2019 04:00 PM ET
After-Market: $12.10 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
[EPZM]
Reports for Purchase
Showing records 1 - 20 ( 490 total )
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
EPZM Gets Scooped Up By Ipsen; Downgrade to N
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
ASCO 2022 Roundup for Covered Companies (Part 2)
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
ASCO 2022 Roundup for Covered Companies (Part 1)
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
SYMPHONY-1 Safety Run-in Update Bodes Well for Phase 3 Portion
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
EHA 2022 Abstract Roundup For Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
Thoughts Ahead of 2H22 Readout on Tazverik + enzalutamide in mCRPC; Reit. Buy and Lowering PT to $8 from $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A